Safety of an investigational formulation of budesonide (budesonide oral suspension) for eosinophilic oesophagitis: an integrated safety analysis of six phase 1-3 clinical trials.

Ikuo Hirano,Evan S Dellon,Sandeep K Gupta,David A Katzka,Margaret H Collins,Abigail M Wojtowicz,Brian Terreri,Wenwen Zhang,Mena Boules,Siddharth Bhatia,Nirav K Desai

Alimentary pharmacology & therapeutics（2023）

引用 3|浏览51

暂无评分

摘要

SHP621-101 (no clinical trials registration number), MPI 101-01 (NCT00762073), MPI 101-06 (NCT01642212), SHP621-301 (NCT02605837), SHP621-302 (NCT02736409) and SHP621-303 (NCT03245840).

查看译文

关键词

adverse event,eosinophilic esophagitis,exposure-adjusted incidence rate,oesophageal eosinophilia,safety integration,swallowed topical corticosteroid

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要